Investment, Funding & Disinvestments

AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

The company plans to develop the first phase of this facility on a 10,000 square metre site with an initial investment of RO 15 million (USD39 million).

Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.

The company plans to bring Neopak Glass Prefillable Syringe production to its long-established facility in Columbus, Nebraska.

WHX in Dubai has expanded its exhibition space by 15% compared to the previous year, preparing to welcome 4,300 exhibitors and attract 235,000 professional visits from representatives across more than 180 countries.

Caldera raised USD75 million in a Series A financing round led by Atlas Venture, LAV, and venBio, followed by an additional USD37.5 million in a Series A-1 round led by Omega Funds.

This new 35,000 square foot, purpose-built site represents Novartis’s fourth dedicated RLT facility.

The government has fully funded the first phase of the vaccine manufacturing facility, which has already reached completion.

The Advisory Board will play a central role in steering the strategic direction of the Pura Longevity Clinic, PureHealth’s pioneering center focused on personalized health longevity and precision medicine.